CD34 and CD38 are prognostic biomarkers for acute B lymphoblastic leukemia

被引：28

作者：

Jiang Z. ^{[1
,2
,3
]}

Wu D. ^{[1
,2
,3
]}

Lin S. ^{[1
,2
,3
]}

Li P. ^{[1
,2
,3
]}

机构：

[1] State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Science Park, Guangzhou, Guangdong

[2] Key Laboratory of Regenerative Biology, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou

[3] Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine, South China Institute for Stem Cell Biology and Regenerative Medicine, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou

来源：

Biomarker Research | / 4卷 / 1期

基金：

中国国家自然科学基金;

关键词：

Acute Myeloid Leukemia; Acute Lymphocytic Leukemia; CD38 Expression; Acute Leukemia; Leukemic Stem Cell;

D O I：

10.1186/s40364-016-0080-5

中图分类号：

学科分类号：

摘要：

CD34 and CD38 proteins are usually used as surface markers to identify HSCs and Leukemic stem cells. However, there have been cases that lacked CD34 or CD38 protein but still had leukemia initiating capacity in B-ALL suggesting the restrictive of these two markers. CD34 and CD38 expression were detected in most B-ALL and can serve as a specific biomarker for the prognosis of this subset of leukemia. Lack of CD34 or high CD38 expression is associated with favorable prognosis. © The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

引用

共 28 条

[1]

Liew E., Atenafu E.G., Schimmer A.D., Yee K.W., Schuh A.C., Minden M.D., Gupta V., Brandwein J.M., Outcomes of adult patients with relapsed acute lymphoblastic leukemia following frontline treatment with a pediatric regimen, Leuk Res, 36, 12, pp. 1517-1520, (2012)

[2]

Larson S., Stock W., Progress in the treatment of adults with acute lymphoblastic leukemia, Curr Opin Hematol, 15, 4, pp. 400-407, (2008)

[3]

Pui C.H., Evans W.E., Treatment of acute lymphoblastic leukemia, N Engl J Med, 354, 2, pp. 166-178, (2006)

[4]

Pui C.H., Robison L.L., Look A.T., Acute lymphoblastic leukaemia, Lancet, 371, 9617, pp. 1030-1043, (2008)

[5]

NCCN Clinical Practice Guidlines in Oncology-Acute Lymphoblastic Leukemia (2016 Version I) [DB/OL]

[6]

Magee J.A., Piskounova E., Morrison S.J., Cancer stem cells: Impact, heterogeneity, and uncertainty, Cancer Cell, 21, 3, pp. 283-296, (2012)

[7]

Clarke M.F., Dick J.E., Dirks P.B., Eaves C.J., Jamieson C.H.M., Jones D.L., Visvader J., Weissman I.L., Wahl G.M., Cancer stem cells-Perspectives on current status and future directions: AACR workshop on cancer stem cells, Cancer Res, 66, 19, pp. 9339-9344, (2006)

[8]

Huntly B.J., Gilliland D.G., Leukaemia stem cells and the evolution of cancer-stem-cell research, Nat Rev Cancer, 5, 4, pp. 311-321, (2005)

[9]

Bonnet D., Dick J.E., Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell, Nat Med, 3, 7, pp. 730-737, (1997)

[10]

Cobaleda C., Gutierrez-Cianca N., Perez-Losada J., Flores T., Garcia-Sanz R., Gonzalez M., Sanchez-Garcia I., A primitive hematopoietic cell is the target for the leukemic transformation in human philadelphia-positive acute lymphoblastic leukemia, Blood, 95, 3, pp. 1007-1013, (2000)

← 1 2 3 →